As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of TuHURA Biosciences, Inc. The largest reported stake is Highbridge Capital Management, LLC's, at 9.1%. 6 filings are on record since July 29, 2025 (Schedule 13G, February 17, 2026).
Sell to companies like TuHURA Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: James A. Bianco, M.D. · Sole voting: 3,085,519 · Shared voting: 0 · Sole dispositive: 3,085,519 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-08-28
- · Holder: Highbridge Capital Management, LLC · Percent: 9.1% · SCHEDULE 13G
- · Holder: The Vanguard Group · Percent: 4.44% · SCHEDULE 13G/A
- · Holder: CA Patel F&F Investments, LLC · Percent: 0.9% · SCHEDULE 13G/A
- · Holder: KP Biotech Group LLC · Percent: 0.9% · SCHEDULE 13G/A
TuHURA Biosciences, Inc. has 6 Schedule 13D or 13G filings on record since 2025-07-29. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Highbridge Capital Management, LLC | 9.1% | 6,060,608 | SCHEDULE 13G, 2026-02-17 | 2025-12-31 |
| James A. Bianco, M.D. | 4.6% | 3,085,519 | SCHEDULE 13D/A, 2026-08-28 | 2026-08-18 |
| The Vanguard Group | 4.44% | 2,269,666 | SCHEDULE 13G/A, 2025-10-31 | 2025-09-30 |
| CA Patel F&F Investments, LLC | 0.9% | 447,232 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-12 |
| KP Biotech Group LLC | 0.9% | 447,232 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-12 |
Holding shares or following this stake? See who's behind TuHURA Biosciences, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on TuHURA Biosciences, Inc. and the records around it.
TuHURA Biosciences, Inc. elsewhere on the record
- Form D filing Nov 2025
- Form D filing Jun 2025
- Who owns it
Companies that share a holder
- Highbridge Capital Management, LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch TuHURA Biosciences, Inc.
Get an email when TuHURA Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on TuHURA Biosciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on TuHURA Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on TuHURA Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| James A. Bianco, M.D. | 3,085,519 | 0 | 3,085,519 | 0 | SCHEDULE 13D/A, 2026-08-28 |
The latest filing identifies TuHURA Biosciences, Inc. by CUSIP 898920103 and gives its principal executive office as 10500 UNIVERSITY CENTER DR., SUITE 110, TAMPA, FL 33612 (SCHEDULE 13D/A, 2026-08-28).
Source of funds (Item 3)
Item 3 of the Original Schedule 13D is hereby amended and restated in its entirety as follows: The Reporting Person is filing this Amendment to report that his beneficial ownership of Common Stock has fallen below 5% of the outstanding Common Stock. This decrease in beneficial ownership percentage resulted from the dilution of the Reporting Person's holdings due to an increase in the Issuer's issued and outstanding shares of Common Stock issued as a result of the Fee Letter.James A. Bianco, M.D., SCHEDULE 13D/A, 2026-08-28
Purpose of Transaction (Item 4)
James A. Bianco, M.D.
Item 4 of the Original Schedule 13D is hereby amended and supplemented to add the following: As described in Item 5, as a result of the issuance by the Issuer of additional shares of Common Stock, and not as a result of any acquisition or disposition of securities by the Reporting Person, the Reporting Person ceased to be the beneficial owner of more than five percent of the outstanding Common Stock on August 18, 2026. Accordingly, this Amendment constitutes the final amendment to the Schedule 13D, and the Reporting Person's reporting obligations under Section 13(d) of the Act with respect to the Common Stock are terminated. The Reporting Person continues to serve as the President and Chief Executive Officer and a director of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2026-08-28
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | The Vanguard Group | 5.11% | SCHEDULE 13G |
| 2025-08-14 | CA Patel F&F Investments, LLC | 0.9% | SCHEDULE 13G/A |
| 2025-08-14 | KP Biotech Group LLC | 0.9% | SCHEDULE 13G/A |
| 2025-10-31 | The Vanguard Group | 4.44% | SCHEDULE 13G/A |
| 2026-02-17 | Highbridge Capital Management, LLC | 9.1% | SCHEDULE 13G |
| 2026-08-28 | James A. Bianco, M.D. | 4.6% | SCHEDULE 13D/A |
Questions about who owns TuHURA Biosciences, Inc.
Who owns TuHURA Biosciences, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of TuHURA Biosciences, Inc.: Highbridge Capital Management, LLC (9.1%, Schedule 13G, filed 2026-02-17).
When did Highbridge Capital Management, LLC buy into TuHURA Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Highbridge Capital Management, LLC on this page is the Schedule 13G, filed 2026-02-17, reporting 9.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for TuHURA Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2025 | Form D, private offering | $1.50M sold | Form D page | Source |
| June 13, 2025 | Form D, private offering | $2.23M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for TuHURA Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.